# A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)

> **NCT00486018** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 397 (actual)

## Conditions studied

- Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** Ranibizumab injection 0.3 mg
- **DRUG:** Ranibizumab injection 0.5 mg
- **DRUG:** Sham injection

## Key facts

- **NCT ID:** NCT00486018
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-05
- **Final completion:** 2009-11
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2017-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00486018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00486018, "A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00486018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*